Reflecting on a Decade of Sofosbuvir Use for Hepatitis C Virus Treatment

G&H  Sofosbuvir was approved with ribavirin or pegylated interferon plus ribavirin just over 10 years ago for the treatment of hepatitis C virus infection. Thinking back […]

Hepatitis C Virus Elimination in the United States: Challenges, Progress, and Future Steps 

Abstract: Hepatitis C virus (HCV) infection is a major public health challenge with a simple, highly efficacious, all-oral therapy (direct-acting antivirals) that can achieve cure. Owing […]

Gastro-Hep News

COVID-19 Assistance Program Provides Crohn’s Disease Patients With Access to Serum-Based Test An assistance program (Monitr COVID-19 Assistance Program, Prometheus Biosciences) has been launched to provide […]

Update on the Treatment of Hepatitis C Virus Infection in Patients With Cirrhosis

  G&H  What is the prevalence of cirrhosis in patients with hepatitis C virus infection, and has it changed over time? PP  It is generally accepted […]

Gastro-Hep News

US Food and Drug Administration Approves Use of Colorectal Cancer Screening Test in Younger Adults On September 23, 2019, the US Food and Drug Administration (FDA) […]

Gastro-Hep News

First-Degree Relatives of Individuals With Celiac Disease at Higher Risk of Diagnosis First-degree relatives (FDRs) of individuals diagnosed with celiac disease (CD) have an increased risk […]

Gastro-Hep News

US Preventive Services Task Force Reaffirms Hepatitis B Virus Screening in Pregnant Women All pregnant women should still b8e screened for hepatitis B virus (HBV) infection […]

A Simplified Algorithm for the Management of Hepatitis C Infection

Proceedings From a Consensus Meeting • September 2018   Abstract: Elimination of hepatitis C virus (HCV) infection as a public health threat is a goal of […]

Highlights in Hepatitis C Virus From the 2018 AASLD Liver Meeting

Highlights in Hepatitis C Virus From the 2018 AASLD Liver Meeting A Review of Selected Presentations From the 2018 AASLD Liver Meeting • November 9-13, 2018 […]

Elimination of Hepatitis B and C Virus Infections

G&H  Is it feasible to eliminate hepatitis B and C virus infections in the United States? AA  Hepatitis B virus (HBV) and hepatitis C virus (HCV) […]

Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection

  Abstract: In 2016, the US Food and Drug Administration issued a warning about the risk of hepatitis B virus (HBV) reactivation in some patients receiving […]

Gastro-Hep News

US Food and Drug Administration Approves 8-Week Treatment for Pangenotypic Hepatitis C Virus Infection On August 3, 2017, the US Food and Drug Administration (FDA) approved […]

Gastro-Hep News

US Food and Drug Administration Approves Treatment for Chronic Hepatitis C Virus Genotypes 1 Through 6 On July 18, 2017, the US Food and Drug Administration […]

Gastro-Hep News

Committee for Medicinal Products for Human Use Votes for 8-Week Treatment Option for Hepatitis C Virus Infection On February 28, 2017, the Committee for Medicinal Products […]

New Therapies for Hepatitis C Virus Infection

  Abstract:  Approximately 350 million people worldwide are infected with hepatitis C virus (HCV), which is associated with morbidity and mortality related to cirrhosis, hepatocellular carcinoma, […]

The Possible Association Between DAA Treatment for HCV Infection and HCC Recurrence

Gastroenterology & Hepatology Volume 12, Issue 12, December 2016 Robert S. Brown, Jr, MD, MPH Gladys and Roland Harriman Professor of Medicine Clinical Chief, Division of […]

Iron Overload in Patients With Chronic Liver Disease

G&H How common is iron overload in patients with chronic liver disease? KK  Some degree of iron overload is present in anywhere from 10% to 30% […]

Global Elimination of Hepatitis C Virus

Gastroenterology & Hepatology October 2016, Volume 12, Issue 10 John W. Ward, MD Director, Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia […]

Direct-Acting Antiviral Agents in Patients with Hepatitis C Cirrhosis

Patients with cirrhosis who are infected with hepatitis C virus (HCV) are the most in need of antiviral treatment. Virologic cure improves fibrosis and quality of life while reducing liver-related morbidity and mortality. In mid-2011, the addition of direct-acting antiviral agents (DAAs)—the protease inhibitors boceprevir (Victrelis, Merck) and telaprevir (Incivek, Vertex)—to pegylated interferon a-2a/b and ribavirin revolutionized the treatment of HCV infection by increasing cure rates across all fibrosis scores in patients with genotype 1 HCV infection. However, patients with advanced fibrosis or cirrhosis are the most difficult to treat, and the addition of DAAs increases treatment side effects as well as potency. Five phase III DAA trials have been published to date, but they contain limited data on patients with cirrhosis. This review will examine the available data and will describe the evolution of HCV therapy in patients with cirrhosis from the standard-of-care therapy of the past decade into the new era of DAAs

Millennium Medical Publishing, Inc